Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dora Jericevic

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Urology Practice|January 16, 2024
Who Progresses to Third-Line Therapies for Overactive Bladder? Trends From the AQUA RegistryDora Jericevic, Katherine Shapiro, Max Bowman, et al.
Urology|December 11, 2023
Factors Influencing Medication Selection for Management of Overactive Bladder: Trends and Insights From AUA Quality RegistryMax Bowman, Camille A Vélez, Dora Jericevic, et al.
Urology|August 22, 2020
Mirabegron Versus Solifenacin in Multiple Sclerosis Patients With Overactive Bladder Symptoms: A Prospective Comparative Nonrandomized StudyBenjamin M Brucker, Dora Jericevic, Temitope Rude, et al.
Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society|August 28, 2019
Diagnosis and treatment of urinary and sexual dysfunction in hereditary TTR amyloidosisImad Bentellis, Gérard Amarenco, Xavier Gamé, et al.
Urology|April 26, 2021
Estimation of Urinary Frequency: Does Question Phrasing Matter?Rachael D Sussman, Christina Escobar, Dora Jericevic, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Urology Practice|January 16, 2024
Who Progresses to Third-Line Therapies for Overactive Bladder? Trends From the AQUA RegistryDora Jericevic, Katherine Shapiro, Max Bowman, et al.
Urology|December 11, 2023
Factors Influencing Medication Selection for Management of Overactive Bladder: Trends and Insights From AUA Quality RegistryMax Bowman, Camille A Vélez, Dora Jericevic, et al.
Urology|August 22, 2020
Mirabegron Versus Solifenacin in Multiple Sclerosis Patients With Overactive Bladder Symptoms: A Prospective Comparative Nonrandomized StudyBenjamin M Brucker, Dora Jericevic, Temitope Rude, et al.
Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society|August 28, 2019
Diagnosis and treatment of urinary and sexual dysfunction in hereditary TTR amyloidosisImad Bentellis, Gérard Amarenco, Xavier Gamé, et al.
Urology|April 26, 2021
Estimation of Urinary Frequency: Does Question Phrasing Matter?Rachael D Sussman, Christina Escobar, Dora Jericevic, et al.
Pageof 2